Merger between BerGenBio ASA and Oncoinvent ASA

Merger between BerGenBio ASA and Oncoinvent ASA
EGM 4 August 2025Webcasts 2 July 2025
Background
DecorationDecoration

Learn About Us

Read more

Latest news

Read more
Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue

Read more

BerGenBio ASA: Updated information regarding the contemplated Rights Issue and Merger

Read more

BerGenBio First half results 2025

Read more

BerGenBio ASA – Updated key information related to the rights issue

Read more

BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue

Read more

BerGenBio ASA: Notice of Extraordinary General Meeting

Read more

BerGenBio ASA – Key information related to the rights issue

Read more

Announcement of fully underwritten rights issue

Read more

BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

Read more
All news